Acetazolamide

Generic Name: Acetazolamide

Drug Type: Small Molecule

Chemical Formula: C_₄H_₆N_₄O_₃S_₂

CAS Number: 59-66-5

Unique Ingredient Identifier: O3FX965V0I

Background: One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)

Indication: For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies; chronic simple (open-angle) glaucoma

Associated Conditions: Acute angle-closure glaucoma, Edema, Familial periodic paralysis, Generalized Tonic-Clonic Seizures, Metabolic Alkalosis, Open Angle Glaucoma (OAG), Other and unspecified effects of high altitude, Cystine renal calculi, Drug-induced edema, Nonuveitic secondary glaucoma, Salicylate intoxication

Associated Therapies: Urine alkalinization therapy

Clinical Trials

Acetazolamide or Metolazone in Acute Heart Failure

Not Applicable

Not yet recruiting

Conditions: Heart Failure Acute
Decompensated Heart Failure

Interventions: Drug: Acetazolamide 250 MG
Drug: Metolazone 2.5 MG
Drug: Furosemide Injection

First Posted Date: 2024-02-22

Last Posted Date: 2024-03-18

Lead Sponsor: Clinica Alemana de Santiago

Target Recruit Count: 1050

Registration Number: NCT06273397

Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload

Phase 4

Recruiting

Conditions: Acute Heart Failure

Interventions: Other: Double-placebo
Drug: Metolazone 2.5 MG
Drug: Acetazolamide

First Posted Date: 2023-12-12

Last Posted Date: 2025-02-20

Lead Sponsor: Johannes Grand

Target Recruit Count: 939

Registration Number: NCT06166654

Locations: 🇩🇰
Amager-Hvidovre Hospital, Hvidovre, Capital Region Of Denmark, Denmark
🇩🇰
Bispebjerg Hospital, Copenhagen, Denmark
🇩🇰
Herlev-Gentofte hospital, Copenhagen, Denmark

RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA

Phase 2

Active, not recruiting

Conditions: Obstructive Sleep Apnea

Interventions: Drug: IHL-42X High Dose
Drug: Placebo
Drug: IHL-42X (Optimal Dose)
Drug: IHL-42X Low Dose
Drug: Dronabinol
Drug: Acetazolamide

First Posted Date: 2023-11-24

Last Posted Date: 2025-04-20

Lead Sponsor: Incannex Healthcare Ltd

Target Recruit Count: 560

Registration Number: NCT06146101

Locations: 🇺🇸
Exalt Clinical Research, Chula Vista, California, United States
🇺🇸
CenExel CNS- Los Alamitos, Long Beach, California, United States
🇺🇸
Teradan Clinical Trials, Valrico, Florida, United States

and more 17 locations

The AXIS Study: the Efficacy of Acetazolamide for the Treatment of Cystoid Fluid Collections in Retinoschisis

Phase 2

Completed

Conditions: Retinoschisis

Interventions: Drug: Acetazolamide

First Posted Date: 2023-11-02

Last Posted Date: 2024-12-06

Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Target Recruit Count: 19

Registration Number: NCT06114537

Locations: 🇳🇱
Amsterdam University Medical Centers, Amsterdam, Noord-Holland, Netherlands

Carbonic Anhydrase Inhibitors and Carbonation: A Novel Approach to Reduce Soda Consumption

Early Phase 1

Conditions: Obesity

Interventions: Drug: Acetazolamide

First Posted Date: 2023-10-31

Last Posted Date: 2024-05-07

Lead Sponsor: University of Arizona

Target Recruit Count: 44

Registration Number: NCT06110078

Locations: 🇺🇸
College of Medicine Phoenix U of Arizona, Phoenix, Arizona, United States

Acetazolamide as a Means to Mitigate Falling Ventilatory Drive and Drive-dependent OSA

Phase 1

Recruiting

Conditions: OSA

Interventions: Drug: Placebo
Drug: Acetazolamide

First Posted Date: 2023-10-19

Last Posted Date: 2024-03-04

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 36

Registration Number: NCT06091085

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Managing Opioid Related Sleep Apnea With Acetazolamide

Phase 2

Recruiting

Conditions: Sleep-Disordered Breathing
Obstructive Sleep Apnea
Central Sleep Apnea
Chronic Pain
Opioid Use

Interventions: Drug: Acetazolamide
Other: Placebo

First Posted Date: 2023-09-21

Last Posted Date: 2025-04-24

Lead Sponsor: University of California, San Diego

Target Recruit Count: 34

Registration Number: NCT06043830

Locations: 🇺🇸
University of California San Diego, San Diego, California, United States

Diuretic Strategies in Acute Heart Failure Patients At High Risk for Diuretic Resistance

Phase 4

Terminated

Conditions: Diuretic Resistance
Acute Heart Failure

Interventions: Drug: Furosemide
Drug: Metolazone
Drug: Acetazolamide

First Posted Date: 2023-08-14

Last Posted Date: 2025-02-14

Lead Sponsor: Stadtspital Zürich

Target Recruit Count: 13

Registration Number: NCT05986773

Locations: 🇨🇭
Stadtspital Zürich, Zürich, Switzerland

Endotypic Traits and Obstructive Sleep Apnea Surgery

Phase 2

Recruiting

Conditions: Obstructive Sleep Apnea

Interventions: Drug: Acetazolamide 500 MG QHS
Drug: Eszopiclone 3 mg QHS

First Posted Date: 2023-07-20

Last Posted Date: 2025-03-13

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 150

Registration Number: NCT05953610

Locations: 🇺🇸
UCLA Santa Monica Medical Center, Santa Monica, California, United States
🇺🇸
UCLA Westwood, Westwood, California, United States

Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs

Phase 1

Completed

Conditions: Obstructive Sleep Apnea

Interventions: Drug: Dronabinol 2.5 MG
Drug: IHL42X
Drug: Acetazolamide 250 MG

First Posted Date: 2023-05-12

Last Posted Date: 2025-01-17

Lead Sponsor: Incannex Healthcare Ltd

Target Recruit Count: 125

Registration Number: NCT05857384

Locations: 🇦🇺
CMAX, Adelaide, South Australia, Australia
🇦🇺
Nucleus Network Pty Ltd, Melbourne, Victoria, Australia
🇦🇺
Nucleus Network Pty Ltd [Commercial Road], Melbourne, Victoria, Australia

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy